GB0002952D0 - Process for producing kahalalide F compounds - Google Patents

Process for producing kahalalide F compounds

Info

Publication number
GB0002952D0
GB0002952D0 GBGB0002952.0A GB0002952A GB0002952D0 GB 0002952 D0 GB0002952 D0 GB 0002952D0 GB 0002952 A GB0002952 A GB 0002952A GB 0002952 D0 GB0002952 D0 GB 0002952D0
Authority
GB
United Kingdom
Prior art keywords
kahalalide
compounds
producing
leads
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0002952.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Priority to GBGB0002952.0A priority Critical patent/GB0002952D0/en
Publication of GB0002952D0 publication Critical patent/GB0002952D0/en
Priority to CA2399187A priority patent/CA2399187C/en
Priority to AU32086/01A priority patent/AU783542B2/en
Priority to DE60130192T priority patent/DE60130192T2/de
Priority to PL356800A priority patent/PL207121B1/pl
Priority to EP07010878A priority patent/EP1829889A3/en
Priority to NZ520488A priority patent/NZ520488A/en
Priority to CN200810178807.9A priority patent/CN101597326B/zh
Priority to RU2002123877/04A priority patent/RU2280039C2/ru
Priority to JP2001558081A priority patent/JP5188665B2/ja
Priority to DK01904169T priority patent/DK1254162T3/da
Priority to ES01904169T priority patent/ES2292558T3/es
Priority to MXPA02007760A priority patent/MXPA02007760A/es
Priority to AT01904169T priority patent/ATE371667T1/de
Priority to US10/182,881 priority patent/US7482429B2/en
Priority to CN01807743A priority patent/CN1422278A/zh
Priority to EP01904169A priority patent/EP1254162B1/en
Priority to KR1020027010355A priority patent/KR100871489B1/ko
Priority to PT01904169T priority patent/PT1254162E/pt
Priority to HK02108862.6A priority patent/HK1047290B/en
Priority to IL15098101A priority patent/IL150981A0/xx
Priority to SK1124-2002A priority patent/SK11242002A3/sk
Priority to BR0108213-2A priority patent/BR0108213A/pt
Priority to CZ2002-2740A priority patent/CZ304258B6/cs
Priority to HU0301817A priority patent/HUP0301817A3/hu
Priority to EP10178150A priority patent/EP2258715A1/en
Priority to PCT/GB2001/000576 priority patent/WO2001058934A2/en
Priority to UA2002097267A priority patent/UA76949C2/uk
Priority to IL150981A priority patent/IL150981A/en
Priority to NO20023749A priority patent/NO331847B1/no
Priority to BG107020A priority patent/BG65926B1/bg
Priority to CY20071101442T priority patent/CY1106992T1/el
Priority to US12/198,013 priority patent/US20080318849A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
GBGB0002952.0A 2000-02-09 2000-02-09 Process for producing kahalalide F compounds Ceased GB0002952D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds
PCT/GB2001/000576 WO2001058934A2 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds
EP01904169A EP1254162B1 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds
KR1020027010355A KR100871489B1 (ko) 2000-02-09 2001-02-09 카할라이드 화합물
DE60130192T DE60130192T2 (de) 2000-02-09 2001-02-09 Kahalalide f und verwandte verbindungen
PL356800A PL207121B1 (pl) 2000-02-09 2001-02-09 Związek kahalalidowy, zastosowanie związku, kompozycja farmaceutyczna oraz sposób wytwarzania związku kahalalidowego
EP07010878A EP1829889A3 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds
NZ520488A NZ520488A (en) 2000-02-09 2001-02-09 Kahalalide compounds
CN200810178807.9A CN101597326B (zh) 2000-02-09 2001-02-09 kahalalide F 及相关化合物
RU2002123877/04A RU2280039C2 (ru) 2000-02-09 2001-02-09 Кахалалидные соединения
JP2001558081A JP5188665B2 (ja) 2000-02-09 2001-02-09 カハラリド化合物
DK01904169T DK1254162T3 (da) 2000-02-09 2001-02-09 Kahalalid F og beslægtede forbindelser
ES01904169T ES2292558T3 (es) 2000-02-09 2001-02-09 Kahalalido f y compuestos relacionados.
MXPA02007760A MXPA02007760A (es) 2000-02-09 2001-02-09 Compuestos de kahalalida.
AT01904169T ATE371667T1 (de) 2000-02-09 2001-02-09 Kahalalide f und verwandte verbindungen
US10/182,881 US7482429B2 (en) 2000-02-09 2001-02-09 Kahalalide F and related compounds
CN01807743A CN1422278A (zh) 2000-02-09 2001-02-09 kahalalide F及相关化合物
CA2399187A CA2399187C (en) 2000-02-09 2001-02-09 Kahalalide compounds
HK02108862.6A HK1047290B (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds
AU32086/01A AU783542B2 (en) 2000-02-09 2001-02-09 Kahalalide compounds
PT01904169T PT1254162E (pt) 2000-02-09 2001-02-09 Kahalalide f e compostos relacionados
IL15098101A IL150981A0 (en) 2000-02-09 2001-02-09 Kahalalide derivatives and pharmaceutical compositions containing the same
SK1124-2002A SK11242002A3 (sk) 2000-02-09 2001-02-09 Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny
BR0108213-2A BR0108213A (pt) 2000-02-09 2001-02-09 Compostos de cahalalida
CZ2002-2740A CZ304258B6 (cs) 2000-02-09 2001-02-09 Kahalalidová sloučenina, způsob její přípravy, farmaceutický prostředek ji obsahující a její použití
HU0301817A HUP0301817A3 (en) 2000-02-09 2001-02-09 Kahalalide compounds, process for preparing thereof, pharmaceutical compositions comprising them and their use
EP10178150A EP2258715A1 (en) 2000-02-09 2001-02-09 Kahalalide compounds
UA2002097267A UA76949C2 (en) 2000-02-09 2001-09-02 Kahalalide compounds
IL150981A IL150981A (en) 2000-02-09 2002-07-30 Khalalid's History and Pharmaceuticals containing them
NO20023749A NO331847B1 (no) 2000-02-09 2002-08-08 Kahalalid-forbindelse, farmasoytisk preparat som omfatter forbindelsen, anvendelse av forbindelsen for fremstilling av et medikament for behandling av kreft og fremgangsmate for syntetisering av en forbindelse.
BG107020A BG65926B1 (bg) 2000-02-09 2002-08-21 Кахалалидни съединения
CY20071101442T CY1106992T1 (el) 2000-02-09 2007-11-08 Καχαλαλιδη f και συναφεις ενωσεις
US12/198,013 US20080318849A1 (en) 2000-02-09 2008-08-25 Kahalalide F and Related Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds

Publications (1)

Publication Number Publication Date
GB0002952D0 true GB0002952D0 (en) 2000-03-29

Family

ID=9885232

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0002952.0A Ceased GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds

Country Status (27)

Country Link
US (2) US7482429B2 (https=)
EP (3) EP1829889A3 (https=)
JP (1) JP5188665B2 (https=)
KR (1) KR100871489B1 (https=)
CN (2) CN1422278A (https=)
AT (1) ATE371667T1 (https=)
AU (1) AU783542B2 (https=)
BG (1) BG65926B1 (https=)
BR (1) BR0108213A (https=)
CA (1) CA2399187C (https=)
CY (1) CY1106992T1 (https=)
CZ (1) CZ304258B6 (https=)
DE (1) DE60130192T2 (https=)
DK (1) DK1254162T3 (https=)
ES (1) ES2292558T3 (https=)
GB (1) GB0002952D0 (https=)
HU (1) HUP0301817A3 (https=)
IL (2) IL150981A0 (https=)
MX (1) MXPA02007760A (https=)
NO (1) NO331847B1 (https=)
NZ (1) NZ520488A (https=)
PL (1) PL207121B1 (https=)
PT (1) PT1254162E (https=)
RU (1) RU2280039C2 (https=)
SK (1) SK11242002A3 (https=)
UA (1) UA76949C2 (https=)
WO (1) WO2001058934A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
ES2256305T3 (es) 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN110709386B (zh) 2017-03-30 2022-06-07 凯瑞康宁生物工程（武汉）有限公司 双环杂芳基衍生物及其制备与用途
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
ES2947089T3 (es) 2018-09-30 2023-08-01 Xwpharma Ltd Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
KR102881504B1 (ko) 2019-12-20 2025-11-06 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
KR20230058151A (ko) 2020-10-05 2023-05-02 엑스더블유파마 리미티드 감마-하이드록시부티르산 유도체의 변형된 방출 조성물
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
US20230338543A1 (en) * 2022-04-21 2023-10-26 Zevra Therapeutics, Inc. Gamma-hydroxybutyrate delivering compounds and processes for making and using them

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0531472B1 (en) * 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
ATE205854T1 (de) * 1991-11-19 2001-10-15 Amylin Pharmaceuticals Inc Peptide als amylin-agonisten und ihre verwendung
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
ID19609A (id) * 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7476198A (en) * 1997-05-09 1998-11-27 General Hospital Corporation, The Cell proliferation related genes
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
CA2406743A1 (en) * 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
ES2256305T3 (es) 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
US20080318849A1 (en) 2008-12-25
NZ520488A (en) 2005-03-24
BG65926B1 (bg) 2010-05-31
HUP0301817A2 (hu) 2003-09-29
CA2399187C (en) 2011-04-19
HUP0301817A3 (en) 2011-10-28
BG107020A (bg) 2003-05-30
NO20023749D0 (no) 2002-08-08
BR0108213A (pt) 2003-03-05
CN101597326B (zh) 2014-07-09
CN1422278A (zh) 2003-06-04
MXPA02007760A (es) 2002-10-23
UA76949C2 (en) 2006-10-16
EP1829889A3 (en) 2007-09-26
CA2399187A1 (en) 2001-08-16
CN101597326A (zh) 2009-12-09
RU2002123877A (ru) 2004-01-10
EP1829889A2 (en) 2007-09-05
SK11242002A3 (sk) 2003-06-03
CZ304258B6 (cs) 2014-02-05
EP1254162B1 (en) 2007-08-29
CY1106992T1 (el) 2012-09-26
CZ20022740A3 (cs) 2003-01-15
ES2292558T3 (es) 2008-03-16
IL150981A (en) 2013-05-30
AU783542B2 (en) 2005-11-10
NO20023749L (no) 2002-10-07
HK1047290A1 (en) 2003-02-14
ATE371667T1 (de) 2007-09-15
EP2258715A1 (en) 2010-12-08
PL356800A1 (en) 2004-07-12
DE60130192T2 (de) 2008-05-21
PL207121B1 (pl) 2010-11-30
WO2001058934A2 (en) 2001-08-16
WO2001058934A3 (en) 2002-03-21
JP2003522198A (ja) 2003-07-22
KR100871489B1 (ko) 2008-12-05
NO331847B1 (no) 2012-04-23
PT1254162E (pt) 2007-12-03
IL150981A0 (en) 2003-02-12
RU2280039C2 (ru) 2006-07-20
KR20020092951A (ko) 2002-12-12
US20040214755A1 (en) 2004-10-28
DK1254162T3 (da) 2008-01-02
JP5188665B2 (ja) 2013-04-24
DE60130192D1 (de) 2007-10-11
AU3208601A (en) 2001-08-20
EP1254162A2 (en) 2002-11-06
US7482429B2 (en) 2009-01-27

Similar Documents

Publication Publication Date Title
GB0002952D0 (en) Process for producing kahalalide F compounds
TW290540B (https=)
ATE333849T1 (de) In-vitro herstellung von transplantierbarem knorpelgewebe
FR04C0014I2 (https=)
AU1574100A (en) Biological nutrient removal using "the olaopa process"
IL148371A0 (en) Process to separate 1,3-propanediol or glycerol, or a mixture thereof from a biological mixture
HU0201152D0 (https=)
HU9904356D0 (en) Process for producing alfa,alfa-difuoro-beta-silyloxy-1,3-dioxolane-4-propanoic acid esters
AU2002316834A8 (en) Process for the production of l-amino acids by fermentation using coryneform bacteria
GB0123864D0 (en) Acrylic synthetic fiber, use thereof, and process for producing acrylic synthetic fiber
AU8151091A (en) Process for the preparation of insecticidal acaracidal and nematicidal 2-aryl-5-(trifluoromethyl) pyrrole compounds
HU9904315D0 (en) Process for preparing orthoesters
EP1018546A4 (en) Microorganisms that produce 5-aminolevulinate and methods of producing 5-aminolevulinate using the same
GB9511895D0 (en) A plant growth stimulant and a process for producing the plant growth stimulant
AU5190293A (en) Method for the preparation of 2-aryl-5-trifluoromethyl pyrrole compounds
HU904673D0 (en) Process for producing non-tanned biologically stable leather
IL132504A0 (en) Methods for reducing fibrinogen
ZA9811493B (en) Process for producing (r)-3-hydroxy-4-butyrolactone useful for preparing (r)-carnitine
GR3019143T3 (en) Process for the preparation of insecticidal, acaricidal and nematicidal 4-substituted-5-(trifluoromethyl)pyrrole-3-carbonitrile compounds
HUP0000824A1 (en) Immunotolerant prothrombin complex preparation
SG71875A1 (en) Method for preparing hydroperoxides by oxygenation
PL286317A1 (en) Generator for producing intended reaction of living organisms
UA31914A (uk) Препаратдля боротьби з хворобами плодових культур
PL107483U1 (en) Artificial culture bedding element for green-house plant cultures
KR970011768U (ko) 양액 재배용 발포스치로폴 베드

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)